Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)
Titel:
Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)
Auteur:
Moehler, M. Maderer, A. Thuss-Patience, P.C. Brenner, B. Meiler, J. Ettrich, T.J. Hofheinz, R.-D. Al-Batran, S.E. Vogel, A. Mueller, L. Lutz, M.P. Lordick, F. Alsina, M. Borchert, K. Greil, R. Eisterer, W. Schad, A. Slotta-Huspenina, J. Van Cutsem, E. Lorenzen, S.